Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Lineage Cell Therapeutics, Inc. (LCTX) is a Biotechnology company based in US with a market capitalization of $284.2M. Revenue grew 53.2% year-over-year and free cash flow was negative at -$19.4M. This page tracks LCTX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 70 employees · IPO Mar 5, 1992
Valuation
Valuation & price
$1.25as of May 17, 2026· -36.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
6.38
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$284.2M
Market cap
53.2%
Revenue growth (YoY)
94.2%
Gross margin
-$19.4M
Free cash flow (USD)
-$53.4M
Net debt
Net cash position
14.9%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Lineage Cell Therapeutics, Inc.'s market cap?
Lineage Cell Therapeutics, Inc. (LCTX) has a market capitalization of $284.2M.
What is LCTX's P/E ratio?
A meaningful P/E ratio is not available for LCTX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is LCTX's price-to-book (P/B) ratio?
LCTX trades at 6.38 times book value per share.
Are insiders buying LCTX stock?
SEC Form 4 filings show no open-market insider buys at Lineage Cell Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.